A sneak peek into cutting‑edge research and innovations driving next‑generation biopharma — from human health breakthroughs to translational applications in animal health. Explore novel compounds, delivery technologies and cross‑species strategies accelerating Animal Health
The animal health industry is shaped not only by science and capital, but by the people who navigate its toughest moments, unexpected turns, and defining decisions. Linda Rhodes shares a reading from her book exploring the decisions, failures, and turning points that shape careers and why perspective, patience, and judgment matter just as much as speed and scale.
The past 12 months have seen rapid innovation and transformation across the Animal Health industry. Stonehaven Cozmix Group explores advancements in technology and business models shaping the sector’s future, including
Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
Kristin Peck is Chief Executive Officer and serves on the Board of Zoetis, the world’s leading animal health company and a member of the Fortune 500. With more than 20 years of experience in life sciences and animal health, Ms. Peck is a purpose-driven leader passionate about driving growth through innovation, superior customer experience and colleague empowerment.
Since becoming CEO in 2020, Ms. Peck has guided Zoetis through a volatile macro environment to deliver superior financial growth – with average organic operating topline growth rates that have outpaced both industry growth and historic company performance. Under her leadership, the company’s portfolio has grown to include 18 blockbuster products – and Zoetis has established a robust pipeline with 12 more potential blockbusters (products with expected future potential sales of $100M+) on the horizon – in addition to delivering industry-leading operating margins.
Ms. Peck’s transformative leadership has earned significant distinctions, including being named to the TIME100 Health (2025), CNBC Changemakers (2024), Barron’s Top CEOs (2022) lists and being recognized as a Fortune Businessperson of the Year (2020).
Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation, at Pfizer Inc. and as a member of Pfizer's Executive Leadership Team. Earlier in her career, Ms. Peck held roles at Boston Consulting Group, as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.
Ms. Peck serves on the boards of BlackRock (NYSE: BLK), Mayo Clinic, and Business Roundtable.
She earned a bachelor's degree from Georgetown University and an MBA from Columbia Business School.
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees.
For more information, visit www.zoetis.com
